Interferon‐free regimens improve portal hypertension and histological necroinflammation inHIV/HCVpatients with advanced liver disease
Alimentary Pharmacology & Therapeutics2016Vol. 45(1), pp. 139–149
Citations Over TimeTop 10% of 2016 papers
Philipp Schwabl, Mattias Mandorfer, Sabine Steiner, Bernhard Scheiner, David Chromy, Merima Herac, Theresa Bucsics, Hubert Hayden, Katharina Grabmeier‐Pfistershammer, Arnulf Ferlitsch, Georg Oberhuber, Michael Trauner, Markus Peck‐Radosavljevic, Thomas Reiberger
Abstract
Interferon-free therapy reduces PHT and halts histological necroinflammatory activity in the majority of HIV/HCV-coinfected patients after SVR, which may lead to re-compensation of liver function in cirrhosis. Biomarkers could identify patients with persisting hepatic necroinflammation.
Related Papers
- → Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography(2012)343 cited
- → The Prevalence of Liver Steatosis and Fibrosis Assessed by Vibration-Controlled Transient Elastography and Controlled Attenuation Parameter in Apparently Healthy Romanian Medical Students(2021)12 cited
- → Ascites and portal hypertension in three young dogs with non‐fibrosing liver disease(1993)8 cited
- → Brief Review of Portal Hypertension Related Complications(2021)